A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda, +15

Annals of the Rheumatic Diseases

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko, +10

Annals of the Rheumatic Diseases

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

Won Park, Dae‐Hyun Yoo, Pedro C. Miranda, +14

Annals of the Rheumatic Diseases

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn, +15

Gastroenterology

InflammationAnti-inflammatoryControlled TrialGastroenterologySurgery +3

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Byong Duk Ye, Marina Pesegova, Olga Alexeeva, +16

The Lancet

Biosimilar Ct-p13Originator InfliximabGastroenterologyClinical GastroenterologyUlcerative Colitis +3

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Justin Stebbing, Y. Baranau, Valeriy Baryash, +14

The Lancet Oncology

Breast OncologyHealth SciencesMedicineClinical TrialsBreast Cancer +7

Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis

Tsutomu Takeuchi, Hisashi Yamanaka, Yoshiya Tanaka, +5

Modern Rheumatology

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

Dae‐Hyun Yoo, Chang‐Hee Suh, Seung Cheol Shim, +17

Annals of the Rheumatic Diseases

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Won Seog Kim, Christian Buske, Michinori Ogura, +14

The Lancet Haematology

Lymphoid NeoplasiaAdvanced-stage Follicular LymphomaMedicineImmune Checkpoint InhibitorBiosimilar Ct-p10 +7

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Michinori Ogura, Juan‐Manuel Sancho, Seok‐Goo Cho, +21

The Lancet Haematology

Lymphoid NeoplasiaOncologyImmune Checkpoint InhibitorBiosimilar Ct-p10Low-tumour-burden Follicular Lymphoma +6